Global Phenylketonuria (PKU) Market Growth 2023-2029

Global Phenylketonuria (PKU) Market Growth 2023-2029

This report studies the Phenylketonuria (PKU) market. Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorder. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.

This report mainly focuses on the treatment for PKU.

LPI (LP Information)' newest research report, the “Phenylketonuria (PKU) Industry Forecast” looks at past sales and reviews total world Phenylketonuria (PKU) sales in 2022, providing a comprehensive analysis by region and market sector of projected Phenylketonuria (PKU) sales for 2023 through 2029. With Phenylketonuria (PKU) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phenylketonuria (PKU) industry.

This Insight Report provides a comprehensive analysis of the global Phenylketonuria (PKU) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phenylketonuria (PKU) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Phenylketonuria (PKU) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phenylketonuria (PKU) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phenylketonuria (PKU).

The global Phenylketonuria (PKU) market size is projected to grow from US$ 1305 million in 2022 to US$ 2638.6 million in 2029; it is expected to grow at a CAGR of 2638.6 from 2023 to 2029.

In the global Phenylketonuria (PKU) market, the main companies are Biomarin, Mead Johnson, Dr. Schär and Abbott, with a market share of more than 50%. The main regions are North America and Europe, with a market share of more than 70%. Supplements have the largest share of the Phenylketonuria (PKU) market, exceeding 50%. The application scenarios of Phenylketonuria (PKU) are mainly concentrated on Household, with a market share of approximately 70%.

This report presents a comprehensive overview, market shares, and growth opportunities of Phenylketonuria (PKU) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Medications
Supplements
Others

Segmentation by application
Household
Hospital

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biomarin
Mead Johnson
Abbott
Nutricia
Dr. Schär
Vitaflo
Cambrooke
PKU Perspectives
Firstplay Dietary

Key Questions Addressed in this Report

What is the 10-year outlook for the global Phenylketonuria (PKU) market?

What factors are driving Phenylketonuria (PKU) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Phenylketonuria (PKU) market opportunities vary by end market size?

How does Phenylketonuria (PKU) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.